# A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Study · id `cardio:ct-nct02033889` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02033889](<https://clinicaltrials.gov/study/NCT02033889>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02033889

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.

## Technical summary

Registry record NCT02033889. Randomized; double masking; primary purpose treatment. Start 2013-12-13 (actual); primary completion 2017-08-03 (actual). Results posted on 2018-09-10.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 621 participants (enrolled count; ClinicalTrials.gov record NCT02033889, source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)
- Started: 2013-12-13 (actual) (ClinicalTrials.gov record NCT02033889, source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2017-08-03 (actual) (ClinicalTrials.gov record NCT02033889, source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)
- Completion: 2017-08-03 (actual) (ClinicalTrials.gov record NCT02033889, source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2018-09-10 (ClinicalTrials.gov record NCT02033889, source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02033889-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 15 mg
- Intervention (Drug): Placebo to Ertugliflozin
- Intervention (Other): Glimepiride
- Intervention (Drug): Placebo to Glimepiride
- Intervention (Biological): Basal Insulin
- Intervention (Drug): Metformin
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) (`cardio:pubmed-28857451`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial (`cardio:pubmed-30614616`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 80f89f3f6d0073d1691bff71cf119f39de7e1118115211668e09f515f53c55dd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
